Table 2.
Single-SNP analysis in the Discovery sample of FOXO3Avariation and (A) activity of daily living and (B) bone (femur/spine/hip/wrist) fracture
| (A) Activity of daily living (n = 1086) |
(B) Bone fracture (n = 1063) |
||||||
|---|---|---|---|---|---|---|---|
| SNP | β-coef. | p-SNP | 95% CI | SNP | OR | p-SNP | 95% CI |
| rs9400239 | 0.07 | 0.020 | 0.01; 0.14 | rs9486902 | 0.60 | 0.001 | 0.45; 0.81 |
| rs9398172 | 0.07 | 0.021 | 0.01; 0.14 | rs7762395 | 0.57 | 0.001 | 0.42; 0.78 |
| rs13217795 | 0.07 | 0.024 | 0.01; 0.14 | rs479744 | 0.69 | 0.007 | 0.52; 0.90 |
| rs2802292 | 0.07 | 0.026 | 0.01; 0.13 | rs3800231 | 0.72 | 0.008 | 0.57; 0.92 |
| rs2764264 | 0.07 | 0.042 | 0.01; 0.13 | rs9398172 | 0.74 | 0.012 | 0.58; 0.94 |
| rs479744 | 0.07 | 0.055 | −0.01; 0.14 | rs9400239 | 0.75 | 0.017 | 0.59; 0.95 |
| rs3800231 | 0.06 | 0.063 | −0.01; 0.12 | rs2764264 | 0.75 | 0.020 | 0.59; 0.96 |
| rs7762395 | 0.07 | 0.074 | −0.01; 0.15 | rs13217795 | 0.76 | 0.028 | 0.60; 0.97 |
| rs10499051 | 0.08 | 0.133 | −0.02; 0.18 | rs12206094 | 0.77 | 0.035 | 0.61; 0.98 |
| rs12206094 | 0.05 | 0.149 | −0.02; 0.11 | rs2802292 | 0.80 | 0.049 | 0.64; 0.99 |
| rs9486902 | 0.05 | 0.171 | −0.02; 0.13 | rs13220810 | 0.88 | 0.303 | 0.70; 1.12 |
| rs3800232 | 0.04 | 0.392 | −0.05; 0.13 | rs12207868 | 1.17 | 0.362 | 0.83; 1.65 |
| rs12207868 | 0.01 | 0.828 | −0.09; 0.11 | rs10499051 | 1.12 | 0.549 | 0.78; 1.61 |
| rs12212067 | 0.01 | 0.869 | −0.09; 0.10 | rs3800232 | 0.94 | 0.711 | 0.68; 1.30 |
| rs13220810 | -0.01 | 0.905 | −0.07; 0.06 | rs12212067 | 1.03 | 0.874 | 0.73; 1.45 |
The single-SNP tests were the basis of the gene-set analysis in the Discovery sample. n, number of individuals with data; β-coef., beta coefficient; OR, odds ratio; CI, confidence interval; p-SNP values < 0.05 are shown in bold, while p-SNP values > 0.05 < 0.10 are shown in bold and italics.